News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn spinout Ascidian Therapeutics has achieved a significant milestone with the FDA's acceptance of their Investigational New Drug (IND) application for ACDN-01.
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
After emerging from stealth mode in 2023, BlueWhale aims to develop a technology platform and product portfolio that will provide the benefits of cell therapy to patients more quickly.
The report highlights Penn’s significant contributions to the growth of the CGT sector in Greater Philadelphia, including spinning out over 40 CGT companies since 2018.
In the recently released Colliers 2024 Life Sciences Report, Philadelphia ranked #4 nationwide, with Boston, the San Francisco Bay Area and San Diego ranking first, second and third, respectively.
This novel method improves resolution of routine low resolution clinical images, saves MR scan time, and reduces radiation dosage levels for CT scanning.
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia.
The machine is the centerpiece of the new Neuroimaging Facility where scientists will study the mind-brain connection in-depth.